#CUE

Cue Biopharma Shares Surge 41.6% on Positive Phase 2 Clinical Trial Results

Cue Biopharma stock jumped 41.6% as positive Phase 2 data for its urticaria treatment CUE-221 met key clinical endpoints, signaling a potential…